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Population pharmacokinetics of 
remifentanil in critically ill patients 
receiving extracorporeal membrane 
oxygenation
Seungwon Yang1, Hayeon Noh1, Jongsung Hahn1, Byung Hak Jin2,3, Kyoung Lok Min2,  
Soo Kyung Bae4, Jiseon Kim4, Min Soo Park2,3,5, Taegon Hong3, Jin Wi6 & Min Jung Chang  1,2
Extracorporeal membrane oxygenation (ECMO) is associated with pharmacokinetic (PK) changes 
of drugs. It presents considerable challenges to providing optimal dosing regimens for patients 
receiving ECMO. We aimed to describe the population PK of remifentanil in critically ill adult patients 
receiving venoartrial extracorporeal membrane oxygenation (VA-ECMO) and to identify determinants 
associated with altered remifentanil concentrations. The population PK model of remifentanil 
was developed using nonlinear mixed effects modelling (NONMEM). Fifteen adult patients who 
received a continuous infusion of remifentanil during VA-ECMO participated in the study. The PK of 
remifentanil was best described by a one-compartment model with additive and proportional residual 
errors. Remifentanil concentrations were affected by sex and ECMO pump speed. The final PK model 
included the effect of sex and ECMO pump speed on clearance is developed as followed: clearance 
(L/h) = 366 × 0.502sex × (ECMO pump speed/2350)2.04 and volume (L) = 41. Remifentanil volume and 
clearance were increased in adult patients on VA-ECMO compared with previously reported patients not 
on ECMO. We suggest that clinicians should consider an increased remifentanil dosing to achieve the 
desired level of sedation and provide a dosing regimen according to sex and ECMO pump speed.
Extracorporeal membrane oxygenation (ECMO) has been increasingly used over the last decade to augment gas 
exchange and hemodynamic support in critically ill patients with refractory cardiac or respiratory failure1,2. With 
more patients being treated with ECMO, there is an increasing requirement to understand the complicated alter-
ations in drug pharmacokinetics (PK) associated with the introduction of the ECMO system. Critically ill patients 
on ECMO receive multiple drugs, including sedatives, analgesics, antibiotics, and other drugs, to support their 
circulation and underlying medical conditions. The presence of ECMO increases the PK variability of these drugs 
owing to additional extracorporeal circulation3. With these dramatic PK alterations, which can lead to changes 
in drug concentrations, the provision of optimal pharmacotherapy to patients on ECMO remains a considerable 
challenge in clinical settings.
Because ECMO is often complicated by hemodynamic instability in critically ill patients with refractory 
cardiogenic shock, patients on VA-ECMO require adequate sedation and analgesia to minimize oxygen con-
sumption, facilitate ventilation, alleviate patient stress responses and delirium, minimize the risk for catheter 
malposition, and prevent device dislodgement4. Remifentanil is one of the widely used sedative agents in ICU 
patients. Remifentanil is a lipophilic, selective μ-opioid receptor agonist that gives intense sedation and analgesia 
with a quick onset and short duration5. The elimination half-life varies from 10 to 20 min and is unaffected by 
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hepatic or renal function6. Remifentanil rapidly equilibrates between blood and the site of drug effect, suggesting 
that the drug responses are correlated to the blood concentrations, which could be predicted by PK parameters7.
Anticipating the changes of PK in patients on ECMO is important to provide and guide a rational dosing 
regimen. Previous studies reported that PK alterations of drugs induced by the ECMO system are associated 
with an increased volume of distribution (V) and modified clearance (CL)8,9. PKs of drugs may be altered as a 
result of drug adsorption, sequestration, and inactivation in ECMO circuit components10. The varying degree of 
binding to the circuit components depends on the physiochemical properties of the drug, such as molecular size, 
lipophilicity, and plasma protein binding11. Current knowledge regarding PK alterations of drugs in patients on 
ECMO is limited, making it difficult to provide optimal dosing regimens of drugs to this patient population. The 
majority of PK data were limited to neonatal or pediatric patients. To date, although small PK studies of anal-
gosedatives, including midazolam12, morphine8, propofol13, and fentanyl14, in ICU patients on ECMO have been 
emerging, there have been no PK studies regarding remifentanil during ECMO despite its frequent use.
Population PK analysis is a pragmatic approach to describe the drug PK, identify patient-related and clinical 
PK variability, and recommend appropriate dosing regimens based on model simulations.
Therefore, we investigated the population PK of remifentanil in critically ill adults receiving VA-ECMO and 
identified significant covariates associated with remifentanil exposure.
Results
Patient characteristics. Fifteen patients who received remifentanil by continuous infusion during ECMO 
support participated in the study. Table 1 displays select demographics, infusion rates, body mass index (BMI), 
total protein, indications for ECMO, duration of ECMO, and use of CRRT during ECMO for each patient. A 
higher proportion of study participants were male (67%). The median age, weight, BMI, and total protein were 
57 years (interquartile range [IQR], 45, 69 years), 65.4 kg (IQR, 54.5, 70.0 kg), 23.8 kg/m2 (IQR, 21.2, 24.2 kg/
m2), and 4.7 g/dL (IQR, 3.9, 5.3 g/dL), respectively. The patients received a median remifentanil infusion rate of 
0.35 mg/h (IQR, 0.25, 0.35 mg/h). The median duration of ECMO support was 143 h (IQR, 96, 250 h) with median 
ECMO pump speeds of 2350 RPM (IQR, 2302, 2532 RPM). The most prevalent admission diagnosis to an ICU 
included acute myocardial infarction (n = 5) and non-ST-segment myocardial infarction (n = 4). Ten patients 
(67%) received concomitant CRRT during ECMO support.
Population PK analysis. Fifty-five remifentanil concentrations (at least three samples from each of the 15 
patients) were included in the analysis. The observed serum concentration-time profiles of remifentanil were best 
described by a one-compartment model with a zero-order input and first-order output (linear elimination). The 
Patient Sex
Age 
(years)
Weight 
(kg)
BMI (kg/
m2)
Total 
protein 
(g/dL)
Infusion 
rates 
(mg/h) Indications for VA-ECMO
Duration 
of VA-
ECMO (h)
Presence 
of CRRT
1 M 69 69.6 26.1 5.3 0.50 (0.50–0.70) NSTEMI 250 Yes
2 M 62 53.8 18.6 5.3 0.40 Ischemic cardiomyopathy 137 No
3 F 55 60.6 22.2 3.3 0.14 (0.14–0.20) Acute MI 250 Yes
4 F 76 40.8 18.1 3.0 0.30 (0.30–0.35) Acute MI 57 Yes
5 M 63 69.0 23.9 3.9 0.25 (0.25–0.35) Acute MI 139 Yes
6 M 52 70.0 24.2 4.6 0.35 (0.25–0.35) Acute MI 76 Yes
7 M 19 69.9 24.2 3.4 0.35 (0.15–0.35) Pulmonary embolism 96 No
8 M 78 53.0 22.9 4.7 0.35 NSTEMI 234 No
9 F 73 54.5 21.2 4.2 0.25 (0.25–0.35) NSTEMI 48 No
10 M 57 94.0 31.8 5.0 0.35 Coronary artery occlusive disease 312 No
11 M 36 60.0 20.5 5.5 0.35 (0.15–0.35) Myocarditis 106 No
12 F 47 65.4 24.3 6.2 0.35 STEMI 143 Yes
13 M 35 73.0 23.8 5.4 1.0 A. Fib, Bronchiolitis 532 Yes
14 F 57 57.0 22.0 4.4 0.35 Angina pectoris 168 Yes
15 M 45 73.2 24.2 5.0 0.20 Acute MI 257 Yes
Median 57 65.4 23.8 4.7 0.35 143
IQR 45‒69 54.5‒70.0 21.2‒24.2 3.9‒5.3 0.25‒0.35 96‒250
Table 1. Individual baseline characteristics of study patients (n = 15). Data are expressed as count or median 
(range). A. Fib, atrial fibrillation; BMI, body mass index; CRRT, continuous renal replacement therapy; ECMO, 
extracorporeal membrane oxygenation; F, female; IQR, interquartile range; h, hours; MI, myocardial infarction; 
M, male; NTSEMI, non-ST-segment myocardial infarction; STEMI, ST-segment myocardial infarction.
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interindividual variability was estimated only for CL as the addition of interindividual variability to V did not 
improve the fit. The estimate of the interindividual variability on V was near zero likely because of the narrow 
weight range in the patient population. Residual variability was best described by a combined (proportional and 
additive) error model. The eta shrinkage for CL in the base model was small (6%), confirming that our estimates 
were not over-parameterized.
Sex and the ECMO pump speed were significant covariates that statistically improved the base model when 
added to remifentanil CL (ΔOFV = −6.882 for sex; ΔOFV = −4.278 for the ECMO pump speed). Plots of 
Bayesian posterior estimates of parameters showed a linear relationship between remifentanil CL and the ECMO 
pump speed (Fig. 1). The final model including the effect of sex and ECMO pump speed on CL was as follows: CL 
(L/h) = 366 × 0.502sex × (ECMO pump speed/2350)2.04, where female = 0 and male = 1 and V (L) = 41.
Table 2 summarizes the model-derived final population PK parameters for remifentanil with its associated 
interindividual variability and median parameter estimates with 95% CIs from 5000 bootstrap replications. The 
PK estimates obtained from the final model were similar to those generated from bootstrap replications, indicat-
ing good precision in the final model.
Figure 2 shows basic goodness-of-fit plots for the final population PK models for remifentanil. An exami-
nation of the goodness-of-plots demonstrated that population prediction and individual population prediction 
were evenly distributed across the line of identity. The individual population prediction (r = 0.939) showed an 
improvement over population prediction (r = 0.788), indicating a good model fit. In addition, the conditional 
Figure 1. Plots of Bayesian posterior estimates of clearance (CL) with a covariate. The individual Bayesian 
estimates of CL as a function of extracorporeal membrane oxygenation (ECMO) pump speeds (dots).
Parameters
Final model Bootstrap (n = 5000)a
Population 
estimate (RSE %) 
[shrinkage] Median
95% CI 
(2.5–97.5%)
Fixed effects
θCL 366 (24) 384 253‒705
θV 41 (21) 39.7 27.8‒83.6
θsex on CL 0.502 (26) 0.474 0.226‒0.724
θECMO pump speed 
on CL 2.04 (62) 2.14 0.252‒5.09
Random effects
Interindividual variability (ω)b
ωCL 0.124 (67) [10] 0.121 0.012‒0.265
Residual variability (σ)
σproportional 0.387 (18) 0.372 0.186‒0.497
σadditive 0.111 ng/ml (31) 0.112 ng/ml 0.015‒0.218
Table 2. Final pharmacokinetic model parameters of remifentanil in critically ill patients receiving 
venoarterial extracorporeal membrane oxygenation. a95% CI estimated from 5000 resampled data sets using 
the final population pharmacokinetic model. bInterindividual variability on volume of distribution (V) was 
not estimated. TVCL, typical value of clearance (L/h); TVV, typical value of volume of distribution (L); ωCL, 
interindividual variability of clearance; σproportional, proportional residual error; σadditive, additive residual error.
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weighted residuals were symmetrically distributed around the line of zero (within ± 2 standard deviations of the 
mean) without an obvious trend, indicating no evidence of model misspecification. Overall, the goodness-of-fit 
plots show no clear systematic bias in the structural and residual error models. PcVPCs with 95% prediction 
intervals using the final population PK model are shown in Fig. 3. PcVPC plots showed that most of the observed 
concentrations were overlaid within 95% of the predictive interval of simulated data, suggestive of the adequate 
predictive performance of the final model.
Predicted concentration profiles. Figure 4 shows the simulated remifentanil concentrations affected by 
sex and ECMO pump speeds (range 1700–2900 RPM) for each dose. According to sex and different speeds of 
the ECMO pump, patients may receive corresponding doses to ensure 95% maintain remifentanil concentrations 
≥1.5 ng/mL15 throughout the treatment of VA-ECMO.
 (1) For female patients: pump speed 1700–2000 RPM, ≥0.42 mg/h; 2000–2900 RPM, ≥0.63 mg/h
 (2) For male patients: pump speed 1700–2000 RPM, ≥0.21 mg/h; 2000–2900 RPM, ≥0.42 mg/h
Discussion
In this prospective cohort study, we investigated the population PK of remifentanil in adult patients on 
VA-ECMO. We found that remifentanil V and CL were increased in adult patients on VA-ECMO compared 
with previously reported patients not on ECMO, and we identified two significant determinants that affected 
remifentanil concentrations: sex and ECMO pump speed. The study results implied that patients on VA-ECMO 
require an increased dose of remifentanil to reach the therapeutic sedation level. Moreover, remifentanil dosing 
could be adjusted according to sex and ECMO pump speed. To our knowledge, this is the first study to develop 
Figure 2. Goodness-of-fit plots of the final population pharmacokinetics (PK) model for continuous 
remifentanil infusion in critically ill patients on ECMO. Observed remifentanil concentrations vs. (a) 
population-predicted concentrations (PRED) and (b) individual-predicted concentrations (IPRED); 
conditional weighted residuals (CWRES) vs. (c) population-predicted concentrations (PRED), and (d) time 
since last dose.
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a population PK model of remifentanil in adult ICU patients on VA-ECMO. By understanding PK changes that 
occur during VA-ECMO, clinicians will be able to provide informed decisions regarding appropriate dosing of 
sedatives to patients on VA-ECMO. This study also added to the paucity of data to guide the optimal dosing of 
sedatives in adult patients on ECMO with regard to contemporary extracorporeal technology.
In our cohort of VA-ECMO patients, the PK of remifentanil during continuous infusion was well described 
using a one-compartment model. Remifentanil PK has previously been described with one-compartment15–17 or 
two-compartment models18,19. The selection of different models may be because of differences in dosing regimen, 
sampling scheme, study population, and analytical method. Nevertheless, a model validation showed that PK 
estimates had good precision and were reasonably unbiased in the present study.
The findings of the present study demonstrated an increased V and CL in ECMO patients compared with 
previously reported non-ECMO patients. Typical V and CL of continuous remifentanil infusion in our cohort 
were 41 L and 366 L/h, respectively. The estimates of V and CL were substantially higher than those in healthy 
volunteers (V range, 18–25 L; CL range, 142–173 L/h) and slightly higher than those in critically ill patients (V 
range, 19–38 L; CL range, 186–297 L/h)7,18,20. This trend of PK alterations was anticipated as V and CL of lipophilic 
drugs, such as remifentanil, are often reported to be increased in ECMO patients21.
An increase in V and CL has been demonstrated in other sedatives administered during ECMO22. Ahsman 
et al. have reported that 20 neonates on VA-ECMO showed increased V and CL of midazolam23. Potential expla-
nations for increased V include critical illness (e.g., systemic inflammation, sepsis) and drug sequestration in 
ECMO circuits10. The sequestration of drugs occurs when the blood is exposed to a large surface area of circuit 
membranes during their transit through the circuit, particularly for lipophilic and protein-bound drugs24. Ex 
vivo studies on the ECMO system revealed that the extent of drug adsorption increases with lipophilicity and the 
degree of bound protein25,26. The adsorption of remifentanil to the ECMO circuit is anticipated as remifentanil 
is moderately lipophilic (log P = 1.25–1.75) and protein bound (70%)27,28. The adsorption of remifentanil may 
result in drug loss over time (reduced drug concentrations) and, subsequently, therapeutic failure. Other expla-
nations for an increased V include an expanded exogenous blood volume (plasma, albumin or saline) required to 
prime the ECMO circuit, an altered serum protein concentration, and massive transfusion4,11,29. Furthermore, the 
typical CL of remifentanil in our cohort moderately increased compared with previously reported non-ECMO 
patients. For drugs previously studied with ECMO, such as midazolam and sildenafil, the reported increase in CL 
was up to 160%23,30. It is likely that CL is increased because the patients had low plasma protein. Decreased plasma 
protein results in a high fraction of the free drug for rapid clearance from the body. Overall, the introduction 
of the ECMO system may have influenced the remifentanil PK and concentration levels25. Therefore, clinicians 
should be aware that an increased dose of remifentanil is required to achieve the desired level of sedation. In 
addition, clinicians should anticipate the need for dose reduction following ECMO removal, owing to a rapid 
decrease in V and CL.
In the present study, the major determinants influencing on the PK of remifentanil were sex and ECMO pump 
speed. Remifentanil CL was higher in female patients than in male patients, resulting in reduced remifentanil 
concentrations in female patients. Females and males differ in body compositions. Females have a greater propor-
tion of body fat and a lower content of body water than males. The differences in body fat compositions may affect 
the PK of many drugs. For lipophilic drugs such as remifentanil, females appear to have reduced drug concen-
trations as a result of higher V and possibly higher CL31. A previous study conducted with a Chinese population 
found that female patients showed higher remifentanil CL than male patients, which is consistent with the present 
study32. Yet, there is no conclusive information indicating that true sex differences exist in the PK of remifentanil 
due to small sample size and uneven sex ratio in the present study. Therefore, a sex-based dosing modification 
should be further investigated.
In addition, we evaluated the effect of ECMO circuit factors, ECMO flow rates and ECMO pump, on the PK of 
remifentanil. ECMO pump speed was positively correlated with remifentanil CL, whereas ECMO flow rates were 
Figure 3. Prediction-corrected visual predictive check of the final population PK model for remifentanil. A 
thousand simulations were performed. Prediction-corrected observed concentrations are shown as open circles. 
The middle solid, lower dashed, and upper dashed lines represent the median, 2.5th, and 97.5th percentiles for 
the observed data, respectively. The shaded areas represent a 95% CI for a simulated predicted median, 2.5th, and 
97.5th percentiles constructed from 1000 simulated datasets of individuals from the original dataset.
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not significantly associated with PK parameters. It is unclear why ECMO pump speed, but not ECMO flow rates, 
affects the PK of remifentanil. However, the components of the ECMO circuit, particularly the centrifugal pump, 
can induce drug degradation33. At a high pump speed, remifentanil may undergo a high degree of spontaneous 
Figure 4. Simulated mean remifentanil concentrations in female vs. male patients with ECMO pump speeds of 
1700, 2000, 2300, 2600, and 2900 RPM. (a1) 0.84 mg/h in female patients, (a2) 0.84 mg/h in male patients, (b1) 
0.63 mg/h in female patients, (b2) 0.63 mg/h in male patients, (c1) 0.42 mg/h in female patients, (c2) 0.42 mg/h 
in male patients, (d1) 0.21 mg/h in female patients, (d2) 0.21 mg/h in male patients, (e1) 0.105 mg/h in female 
patients, and (e2) 0.105 mg/h in male patients. Conc, concentration; ECMO, extracorporeal membrane 
oxygenation; h, hour; RPM, revolution per minute.
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degradation, which can result in increased CL and reduced remifentanil concentrations. Although it is challeng-
ing to arrive at a definite conclusion based on these data, this finding provides clinicians insight into whether 
dosing modification of remifentanil-based on the pump speed may be necessary during VA-ECMO.
The simulations from the final population PK model present the predicted remifentanil exposures affected by 
sex and the ECMO pump speed in VA-ECMO patients by exploring the various dosing scenarios. The clinical 
implications of our findings were examined to determine appropriate dosing regimens at a target concentration 
of ≥1.5 ng/mL15 for optimal sedation. Considering that the median speed of the ECMO pump was 2350 RPM in 
the present study, female patients with a minimum dose of 0.63 mg/h and male patients with a minimum dose of 
0.42 mg/h achieved a target concentration of ≥1.5 ng/mL in most patients.
There are several limitations in the present study. First, although this study was limited by its small sample size 
(n = 15), Shekar et al. estimated that a minimum of 12 patients would be sufficient for a population PK analysis 
in ECMO patients34. Other previous studies included only 9 children and 15 adult ICU patients to develop the 
population PK model of remifentanil15,32. Second, a sparse sampling scheme and few samples failed to describe 
the saturation of the ECMO tubing and/or changes in levels following changing of the ECMO components. It also 
may have affected the precision of PK estimates. Nevertheless, our validation evaluation from the final model 
demonstrated the good estimates of PK parameters to predict remifentanil concentrations. Third, the absence 
of a control group precludes the comparison of non-ECMO patients in our cohort. Fourth, patients had limited 
variability or narrow range in their body weight, limiting the generalizability of the data to other patients. Lastly, 
the variability of ECMO equipment may have a different influence on the PK of remifentanil, limiting the gener-
alizability to other settings.
Ideally, the management of sedation in ICU patients on ECMO should use a personalized approach in deliver-
ing the optimal dosing regimen to each patient. In summary, remifentanil V and CL were increased in VA-ECMO 
patients compared with previously reported non-ECMO patients and significant determinants affecting the PK of 
remifentanil are sex and ECMO pump speed. Based on the results of this study, we suggest that clinicians should 
consider an increased remifentanil dosing during VA-ECMO to achieve the desired sedation level. Despite some 
limitations, this study serves as an initial step toward understanding the remifentanil PK in adult patients on 
VA-ECMO and providing the optimization of pharmacotherapy within this patient population. Future studies 
are warranted to validate our findings from a larger population with the non-ECMO control group. Future studies 
should also consider describing the attainment of sedation goals using pain and agitation scales to make the data 
more clinically relevant.
Methods
Study design and setting. This prospective, cohort study was undertaken in the cardiovascular ICU 
of Severance Cardiovascular Hospital, a university-affiliated tertiary hospital in Seoul, South Korea, between 
January 2015 and December 2016 (ClinicalTrials.gov NCT02581280). The study was approved by the institutional 
review board (IRB) at Severance Hospital (IRB number 4–2014–0919) and conducted in accordance with the 
principles of the Declaration of Helsinki. Written informed consent was obtained from each participant or their 
legally authorized representatives (if the participant lacked the capacity to consent) before any study procedure.
Patients. Patients were eligible for enrollment if they were aged ≥19 years, received remifentanil during 
VA-ECMO support, and hospitalized in a cardiovascular ICU. Patients were excluded if they were pregnant 
or lactating mothers, or were known to be allergic to the remifentanil or any of the remifentanil ingredients, 
were undergoing treatment drugs that may cause potential drug-drug interaction and change the remifentanil 
concentrations.
ECMO system. The ECMO system consists of a centrifugal blood pump with a pump controller (Capiox 
SP®, Terumo Inc., Tokyo, Japan), a polymethylpentene (PMP) circuit (Capiox EBS® with X coating, Terumo 
Inc., Tokyo, Japan) with poly-(2-methoxyethyl acrylate) (PMEA) polymer-coated polyvinylchloride (PVC) tub-
ing and an air-oxygen mixer (Secrist Ind., Anaheim, CA, USA). The centrifugal blood pump was set at an initial 
blow flow of 3.0–4.0 L/min. ECMO equipment was implanted using percutaneous femoral peripheral cannulation 
with a 17-Fr arterial cannula (BioMedicus Medtronic Inc., Minneapolis, MN, USA) and a 21-Fr venous cannula 
(BioMedicus multistage femoral venous cannula).
Study procedures. In this observational study, remifentanil and all other concomitant medications were 
administered at the discretion of the treating physician and were not affected by study procedures. Remifentanil 
(Ultiva®, GlaxoSmithKline, Brentford, UK) was administered via continuous infusion and maintained at a fixed 
infusion rate unless a change in sedation level was detected, as part of the routine course of therapy. No patients 
required the bolus injection of remifentanil during the study.
The following demographic and clinical data from the electronic medical records were collected: age, sex, 
body weight, BMI, remifentanil dose and infusion rate, duration of ECMO, ECMO flow rate, ECMO pump speed, 
use of continuous renal replacement therapy (CRRT), serum creatinine (SCr), total protein, and temperature.
PK sampling was performed during ECMO support. Sparse PK samples for measurement of remifentanil con-
centrations (3 mL) were drawn from dwelling arterial lines at 8–12 (T1), 24 (T2), and 36–48 (T3) h. If remifentanil 
was discontinued during VA-ECMO, serial PK samples were collected immediately before the discontinuation 
and at 5, 10, 15, 25, 30, and 40 min. Blood samples were collected into EDTA-coated tubes, which were directly 
placed on ice, followed by immediate centrifugation and addition of formic acid to EDTA plasma. The superna-
tants were stored at −80 °C until subsequent assay. The remifentanil assay procedures were followed as previously 
described35.
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Remifentanil concentration assay. Remifentanil concentrations were analyzed using a validated liquid 
chromatography-tandem mass spectrometry instrument (Shimadzu Inc. Corp, Kyoto, Japan). Plasma samples 
were denatured with acetonitrile consisting of 1 μg/mL chlorpropamide (IS, internal standard). The mixture was 
vortexed and centrifuged. A chromatographic gradient was applied using a mixture of acetonitrile and water 
(20:80, v/v)with 0.1% formic acid. The assay was validated between 0.05 and 500 ng/mL with an inter-assay coef-
ficient of variation <15% except for the lower limit of quantification (LLOQ). The inter- and intra-assay coeffi-
cients of variation were 5.6% and 0.6%, respectively. The LLOQ for remifentanil was 0.05 ng/mL. The calibration 
curve was linear between 0.05 and 500 ng/mL with an R2 of 0.988.
Population PK modelling. The population PK model for the concentration-time data for remifentanil 
concentrations was developed by using NONMEM® version 7.3. (ICON Development, Ellicott City, MD, USA) 
bundled with a gfortran compiler and Perl-Speaks to NONMEM (PsN) toolkit36. The first-order conditional 
estimation with the interaction (FOCE INTER) approach was used to estimate typical population PK parameters, 
interindividual variability, and residual variability throughout the model development process. Data visualization 
and output evaluation were performed using Pirana® version 2.9.237 and Xpose® version 4.0 (http://xpose.source-
forge.net) in R® version 3.2.1 (http://www.r-project.org)38.
Structural and model development. One- and two-compartment models were evaluated as potential 
structural PK models according to previous studies15,16,18,19,39. For interindividual variability (η) of population PK 
parameters, an exponential variance model was evaluated and assumed to follow a log-normal distribution with 
a mean of zero and a variance of ω2. For residual variability (ε), additive, proportional, and combined additive 
and proportional error models were evaluated and assumed to be normally distributed with a mean of zero and 
a variance of σ2.
Model development and selection were based on the minimum objective function value (OFV), minimiza-
tion successful, the plausibility of model-derived PK parameter estimates relative standard errors (RSE), and a 
visual inspection of graphical goodness-of-fit. A reduction in the OFV of > 3.84 (x2 distribution, the degree of 
freedom = 1) was considered statistically significant (p < 0.05). A goodness-of-fit was assessed by the correlation 
coefficient, and visual inspection of the observed concentrations vs. individual predictions (IPRED), observed 
concentrations vs. population predictions (PRED), and conditional weighted residuals vs. population predictions 
and time.
Covariate model. Potential covariates were tested for their influence on the PK parameters of remifentanil. 
The continuous covariates tested included age (years), body weight (kg), ECMO flow rate (liters per minute, 
LPM), ECMO pump speed (revolutions per minute, RPM), serum creatinine (mg/dL), and temperature (°C). 
These covariates were centered using their median values and evaluated using a power, exponential, and linear 
model. The categorical covariates tested included sex (where female = 0, male = 1) and the presence of CRRT sup-
port (where absent = 0, presence = 1), which were evaluated using a power, exponential, and proportional model. 
Covariates that were biologically or clinically plausible, reduced the OFV by > 3.84 (p < 0.05, x2 distribution, the 
degree of freedom = 1), decreased residual variability, and improved the goodness-of-fit plots were included in 
the final model.
Model diagnostics and validation. The nonparametric bootstrap method (n = 5000) was performed to 
evaluate the precision and stability of the final model. The median with 95% confidence intervals (CI) (2.5–97.5 
percentiles) for the bootstrap replicates was generated and compared with the PK parameter estimates from the 
final model. Moreover, prediction-corrected visual predictive checks (pcVPCs) were performed for model vali-
dation40. A thousand simulated datasets of individuals from the original dataset were graphed and compared with 
prediction-corrected observed concentrations of a continuous infusion of remifentanil, which were overlaid with 
the 95% CIs of the simulated 5th, 50th, and 95th percentile curves.
Simulations. Monte Carlo simulations (n = 5000) were performed using the PK parameters of the final 
model to examine the effect of sex and the ECMO pump speed on predicted remifentanil concentrations and 
propose the dosing regimen. The ECMO pump speeds simulated were 1700, 2000, 2300, 2600, and 2900 RPM in 
female vs. male patients with different dosing regimens. We assumed that remifentanil was continuously infused 
for 2 days with the following infusion rates: 0.84, 0.63, 0.42, 0.21, and 0.105 mg/h. While interpreting the simu-
lation results, a target concentration ≥1.5 ng/mL was considered for optimal sedation according to preliminary 
evidence15.
Data availability. The datasets generated during and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
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